Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

Please enter the email address for your account. A verification code will be sent to you. Once you have received the verification code, you will be able to choose a new password for your account.

THERANEXUS announces the clinical results of its phase 1b study demonstrating the extended pharmacological profile of its drug candidate THN201 compared to donepezil

Download PDF File (381 Ko)

THERANEXUS and Beyond Batten Disease Foundation (BBDF) announce the signing of a worldwide exclusive license for Batten disease drug candidate BBDF-101

Download PDF File (363 Ko)

THERANEXUS reports cash position as of September 30th 2019

Download PDF File (285 Ko)

THERANEXUS announces its first half 2019 results

Download PDF File (285 Ko)

A new milestone reached for Theranexus: inclusion of last patient in phase II trial for THN102 in Parkinson’s patients

Download PDF File (285 Ko)